Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThis change updates the page’s system/release revision label from v3.5.2 to v3.5.3, without altering the study record content.SummaryDifference0.1%

- Check27 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No substantive changes to content or features.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision updated to v3.5.0; previous revision v3.4.3 has been removed.SummaryDifference0.1%

- Check71 days agoChange DetectedThe page shows a revision from v3.4.2 to v3.4.3. This appears to be a minor update with no changes to study content.SummaryDifference0.1%

- Check92 days agoChange DetectedSite-level revision notes show Revision: v3.4.2 with dates 2026-01-26 and 2026-02-12, replacing v3.4.1; this does not affect the study data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check100 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. No visible changes to study content or navigation.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.